What is Integra LifeSciences's market cap?

Integra LifeSciences (IART) has a market capitalization of $1.5B and trades on NASDAQ.

What is Integra LifeSciences's revenue and profitability?

Integra LifeSciences generated $1.6B in trailing twelve-month revenue with a net loss of $7.2M, representing a net margin of -0.4%. Gross margin stands at 52.5%, with free cash flow of -$11.2M. These figures are based on the Q2 2026 filing.

Who are Integra LifeSciences's competitors?

Integra LifeSciences's key competitors include Stryker Corporation, Medtronic, Inc., Organogenesis Holdings Inc., and others. These companies compete in similar markets and product categories.

Who does Integra LifeSciences partner with?

Integra LifeSciences's notable partners include SM USA, Inc., Medtronic plc, Ethicon, Inc..

What subsidiaries does Integra LifeSciences have?

Integra LifeSciences's subsidiaries include Codman Specialty Surgical, BioD LLC, Acclarent, Inc., and others.

Where is Integra LifeSciences headquartered?

Integra LifeSciences is headquartered in United States of America and employs approximately 3,946 people. It has been publicly traded since 1995.

Integra LifeSciences

IART

Integra LifeSciences is a global medical technology company focused on regenerative medicine and neurosurgery.

Market cap

$1.52B+58.1%

Revenue$1.6B+1.6%

Net income-$7.2M+98.6%

Free cash flow-$11.2M-38.8%

EPS (diluted)-$0.09+98.7%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q2 2026 report

July 29, 2026

Revenue$418.8MBeat by $1.2M EPS$0.56Beat by $0.08

Read the full report

Next report

Date not yet announced

Financials

Q2 2026

Income statement

See full

Revenue$418.8M+0.8%

Gross profit$219.7M+5.0%

Operating income$19.3M+104%

Net income$4.5M+101%

EPS (diluted)$0.06+101%

Balance sheet

See full

Cash & equivalents$214.4M-1.6%

Total debt$2.0B+3.2%

Total equity$1.0B+0.5%

Total assets$3.6B-2.8%

Cash flow

See full

Operating cash flow$22.8M+156%

CapEx$12.3M-38.9%

Free cash flow$10.5M+193%

Valuation & ratios

Valuation

See full

Market cap$1.52B+58.1%

Enterprise value$3.26B+20.9%

P/S0.9×+0.3×

Profitability

See full

Gross margin52.5%-0.1pp

Operating margin2.6%+1.3pp

Net margin-0.4%—

Returns & leverage

See full

Return on equity-0.7%—

Debt / equity1.9×+0.1×

Current ratio3.6×+2.4×

Segments

By geography

See full

Asia Pacific$48.7M+2.0%

Europe$42.6M-0.1%

Rest of World$20.4M+7.5%

By segment

See full

Specialty Surgery$309.3M+1.7%

Tissue Reconstruction$109.5M-1.9%

By product

See full

Neurosurgery$213.3M+2.0%

Private Label$28.2M+4.8%

Competitors

By market cap

AbbVie$453.91B+36.3%

Stryker$129.09B-15.7%

Medtronic$107.81B-8.5%

Becton, Dickinson and Company$43.8B-16.5%

STERIS$21.3B-4.5%

IAR

Integra LifeSciences$1.5B+49.2%

MiMedx Group$634.5M-36.7%

Organogenesis Holdings Inc.$328.1M-48.5%

By revenue growth

Organogenesis Holdings Inc.+12.2%

Becton, Dickinson and Company+6.4%

IAR

Integra LifeSciences+1.6%

By net margin

Stryker13.21%+0.9pp

Medtronic13.2%-0.7pp

STERIS13.18%+1.9pp

MiMedx Group7.88%-3.5pp

AbbVie5.79%-1.5pp

Becton, Dickinson and Company5.33%-2.1pp

Organogenesis Holdings Inc.0.528%+4.0pp

IAR

Integra LifeSciences-0.44%+32.4pp

Profile

Integra LifeSciences is a global medical technology company focused on regenerative medicine and neurosurgery. The company develops, manufactures, and markets a diverse portfolio of surgical instruments and tissue-based technologies used in neurocritical care, wound reconstruction, and general surgery. Its core value proposition centers on advancing transformational care through highly differentiated technologies that restore lives.

Competitive position

Integra is the global leader in neurosurgery and a top three U.S. provider of specialty surgical instruments. It holds a leading position in regenerative technology as the first company to receive an FDA claim for dermal tissue regeneration.

GeographiesUnited States, Europe, Asia Pacific, China, Latin America, Canada

Customer segmentsHospitals, Surgical Centers, Clinicians, Integrated Health Networks

Business modelManufacturing, Direct Sales, Private Label, B2B

SuppliersBovine tissue suppliers (U.S. and New Zealand), Specialized third-party handheld instrument vendors, Sterilization service providers, Raw material suppliers (silicone, steel, honey, porcine tissue)

CustomersHospitals, Group Purchasing Organizations (GPOs), Integrated Health Networks, Independent distributors, Private label medical technology partners

CountryUnited States of America

Listed1995

Employees3.9K

CEOStuart Essig

SectorHealthcare

IndustryMedical - Devices

Websiteintegralife.com

FilingsSEC EDGAR

Ask your AI about Integra LifeSciences.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Integra LifeSciences's market cap?: Integra LifeSciences (IART) has a market capitalization of $1.5B and trades on NASDAQ.
What is Integra LifeSciences's revenue and profitability?: Integra LifeSciences generated $1.6B in trailing twelve-month revenue with a net loss of $7.2M, representing a net margin of -0.4%. Gross margin stands at 52.5%, with free cash flow of -$11.2M. These figures are based on the Q2 2026 filing.
Who are Integra LifeSciences's competitors?: Integra LifeSciences's key competitors include Stryker Corporation, Medtronic, Inc., Organogenesis Holdings Inc., and others. These companies compete in similar markets and product categories.
Who does Integra LifeSciences partner with?: Integra LifeSciences's notable partners include SM USA, Inc., Medtronic plc, Ethicon, Inc..
What subsidiaries does Integra LifeSciences have?: Integra LifeSciences's subsidiaries include Codman Specialty Surgical, BioD LLC, Acclarent, Inc., and others.
Where is Integra LifeSciences headquartered?: Integra LifeSciences is headquartered in United States of America and employs approximately 3,946 people. It has been publicly traded since 1995.